Patents by Inventor Kenneth E. Lipson

Kenneth E. Lipson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of adamantane compositions and methods of reducing fibrotic tissue
    Patent number: 12390426
    Abstract: Provided herein are compositions used to reduce fibrotic tissues associated with an integumentary system fibromatosis condition. Methods of using the compositions to reduce fibrotic tissues associated with an integumentary system fibromatosis condition are also disclosed.
    Type: Grant
    Filed: May 10, 2024
    Date of Patent: August 19, 2025
    Assignee: Ventoux Biosciences, Inc.
    Inventors: Kurt Matthew Harrington, Kenneth E. Lipson
  • METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20190127456
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering an anti-CTGF antibody. In particular, the treatment methods provided avoid toxicities associated with approved therapies and also avoid the attenuation of the efficacy of an anti-CTGF antibody caused by these approved therapies.
    Type: Application
    Filed: September 14, 2018
    Publication date: May 2, 2019
    Applicant: FibroGen, Inc.
    Inventors: Seth Porter, Kenneth E. Lipson, Eduard Gorina de Travy, Kin-Hung Peony Yu
  • Treatment method for lung remodeling diseases
    Patent number: 9587016
    Abstract: The present invention relates to methods and medicaments useful for pre-treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: March 7, 2017
    Assignee: FIBROGEN, INC.
    Inventor: Kenneth E. Lipson
  • TREATMENT METHOD FOR LUNG REMODELING DISEASES
    Publication number: 20150376270
    Abstract: The present invention relates to methods and medicaments useful for pre-treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.
    Type: Application
    Filed: June 17, 2015
    Publication date: December 31, 2015
    Inventor: Kenneth E. Lipson
  • Treatment Method For Lung Remodeling Diseases
    Publication number: 20140134181
    Abstract: The present disclosure relates to methods and medicaments useful for pretreatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.
    Type: Application
    Filed: November 7, 2011
    Publication date: May 15, 2014
    Inventor: Kenneth E. Lipson
  • Treatment for Radiation-Induced Disorders
    Publication number: 20120244169
    Abstract: The present invention relates to methods and medicaments useful for treatment of radiation-induced disorders by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods and medicaments for pre-treating individuals having or at risk for having exposure to ionizing radiation to prevent or reduce radiation-induced disorders are also provided.
    Type: Application
    Filed: November 8, 2010
    Publication date: September 27, 2012
    Applicant: FibroGen, Inc.
    Inventor: Kenneth E. Lipson
  • 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
    Patent number: 7157577
    Abstract: The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: January 2, 2007
    Assignee: Sugen Inc.
    Inventors: Peng Cho Tang, Congxin Liang, Todd Miller, Kenneth E. Lipson
  • 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
    Publication number: 20040204407
    Abstract: The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Application
    Filed: March 8, 2004
    Publication date: October 14, 2004
    Applicant: SUGEN Inc.
    Inventors: Peng Cho Tang, Congxin Liang, Todd Miller, Kenneth E. Lipson